TMD-SECURITY
4.6.2020 08:02:04 CEST | Business Wire | Press release
TMD Security announced today the launch of a global program with consulting firm Deloitte to help banks and ATM deployers understand the annual operational cost savings and benefits from replacing physical keys and manual processes with a key-less ATM and Branch Access Management solution. Ten Deloitte customer engagements are planned in EMEA, APAC and the Americas and there is availability for a further ten free custom business case engagements before the end of the year.
“Reducing ATM operational costs has never been more critical than it is today,’’ said Cees Heuker of Hoek, CEO and Founder, TMD Security. “We are proud to announce this global relationship with Deloitte. A custom business case gives valuable insight into an ATM deployer’s specific cost savings and business benefits potential, depending on their ATM network and current access processes. Our clients discover that replacing keys and manual processes with our Access Management solution results in staggering productivity improvements and annual operational cost savings. Also, faced with the health risks associated with the COVID-19 pandemic, removing the need for keys, reducing the number of ‘meet and greets’ with key-holders at service visits, and eliminating the reliance on call centres for providing security codes brings significant safety benefits. Despite the pandemic, we can continue with the Deloitte program because interviews and data gathering can be done remotely. Interest has been strong and we are inviting ATM deployers to reserve one of the remaining slots soon.’’
TMD ATM and Branch Access Management is a key-less, centrally managed secure access solution for all types of ATMs and door locks which remotely validates the IDs of the pre-authorised user, lock and mobile device and checks the pre-approved schedule in a split second at the time of access. Randomly generated, encrypted One-Time-Codes are sent directly to the lock, with a real-time audit trail. TMD’s new Intelligent Alarm Switch integrates pre-authorised activation and deactivation of alarms in the ATM, secure room or branch into the access management solution via TMD’s One Touch Access TM Security mobile app which saves time, reduces false alerts and improves security.
“Our clients recognise that TMD Security is in a unique position to deliver proven and certified security hardware combined with intelligent software because of our sister company TMS ATM Software," added Cees. “This powerful combination of hardware and software means that we are fast to market with innovative, user-friendly access management solutions that can be tailored to our clients’ needs.’’
TMD Security will present real-world facts and figures from ATM deployers who are already reaping the benefits of key-less Access Management in a live webinar hosted by ATM Marketplace.
Company profile
TMD Security is the global leader in ATM security and ATM and Branch Access Management with headquarters in Europe and sales and support in the Americas, EMEA and APAC.
email: accessmanagement@tmdsecurity.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200603005038/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom